Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden

June 08, 2026

Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580). 

Related Content